Joyvie Health Raises $1.04M to Redesign Continence Care

Jan de Vries · 2026-06-05

### A Personal Story That Sparked a Mission Zoe Robson never planned to start a company. But when her father Fred passed away from pancreatic cancer in 2025, she couldn't shake what happened in his final weeks. Fred was 77, active, and sharp-minded. Then, on Christmas Eve 2024, he got a late-stage diagnosis. Eleven weeks later, he was gone. During those weeks, Fred lost bowel control. He had to wear adult nappies. Here's the brutal truth: when stool sits against skin, it breaks it down. Moisture, pathogens, and pH imbalance cause damage that never fully heals. Fred's skin broke down. His dignity went with it, piece by piece. His wife Ruth became his primary caregiver. She carried a burden that was invisible to everyone else and impossibly heavy. "My parents didn't deserve that," Zoe says. "They were both at their most vulnerable, and the product meant to help them was making it worse. The skin breakdown, the shame, the loss of dignity, the weight on my mum. It wasn't from lack of care. It's a design failure." ### The Funding Round Joyvie Health just closed its pre-Seed round, raising about $1.04 million (approximately 897,000 euros). The money comes from an Innovate UK grant plus investments from HERmesa Angels, SyndicateRoom, Lavender Ventures, and several individual angel investors. Gail Armstrong from Lavender Ventures explains: "We are committed to backing founders addressing large, underserved markets with innovative solutions. We believe the market is ripe for innovation, and Joyvie's approach has the potential to deliver significant benefits for individuals, carers, healthcare systems, and the environment."  ### What Makes Joyvie Different Here's the core problem: current continence products trap stool against the skin. That's basically a recipe for skin breakdown and infection. Joyvie's design flips that. Instead of trapping waste, it contains stool in a disposable pouch right after excretion. The result? Early testing shows about 90% less stool-to-skin contact and roughly 70% faster changes. This isn't just about comfort. It's about dignity. It's about reducing the burden on caregivers who often spend hours cleaning and changing loved ones. And it's about preventing the skin damage that leads to infections, hospitalizations, and even more suffering. ### The Bigger HealthTech Picture Joyvie's funding sits within a massive wave of HealthTech investment across Europe in 2026. Here's a quick snapshot of related deals: - Semble raised $37.4 million for healthcare management platforms - Evaro secured $22.6 million for NHS-licensed health services - Recare in Berlin got up to $39.9 million for AI hospital platforms - Tucuvi raised $18.3 million for voice-AI nursing automation - ShanX Medtech landed $25.9 million for antimicrobial-resistance diagnostics Combined, these rounds total over $186 million in related HealthTech funding this year alone. ### The Silent Crisis Faecal incontinence affects an estimated 656 million people globally. Yet the most common non-invasive solution hasn't changed in decades: nappies and pads. It's a massive, underserved market. And it's one where innovation can literally change lives overnight. "Products designed for care should never cause harm," Zoe says. "That's not a vision statement. It's the reason this company exists." ### What's Next With this funding, Joyvie Health plans to continue product development, run clinical trials, and prepare for market launch. The goal is simple: give people their dignity back, reduce caregiver burden, and prove that continence care doesn't have to be a source of shame and skin damage. For Zoe, this is personal. For millions of families, it's desperately needed. And for investors, it's a rare chance to back a solution that addresses a huge, overlooked problem with real innovation.